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Abstract 
 
Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor 
prognosis, as current therapies are ineffective. Despite the increased understanding of the 
molecular biology of mesothelioma, there is still a lack of drugs that dramatically enhance 
patient survival.  
Area Covered: This review discusses recent and complete clinical trials supported by the NIH, 
other U.S. Federal agencies, universities and organizations found on clinicaltrials.gov. Firstly, 
chemotherapy-based trials are described, followed by immunotherapy and multitargeted 
therapy. Then we introduce drug repositing and the use of drug docking as tools to find new 
interesting molecules. Finally, we highlight potential molecular pathways that may play a role 
in mesothelioma biology and therapy. 
Expert Commentary: Numerous biases are present in the clinical trials due to a restricted 
number of cases, inappropriate endpoints and inaccurate stratification of patients which delay 
the finding of a treatment for MPM. The most crucial issue of independent research for MPM 
is the lack of more substantive funding to translate these findings to the clinical setting. 
However, this approach is not necessarily scientific given the low mutational load of 
mesothelioma relative to other cancers, and therefore patients need a more solid rationale to 
have a good chance of successful treatment. 
  
Highlights box 
• Mesothelioma clinical trials rarely met the principal parameters for the design of 
high-quality trials mainly due to the size of the population investigated. 
• Although targeted therapy and immunotherapy, in particular immune checkpoint 
inhibitors, has been approved by the FDA for the treatment of cancers such as 
melanoma, these therapies have shown low clinical benefit for MPM patients 
• The approach of drug repositioning is based on a solid scientific rationale, combined 
with a good clinical trial design and effective endpoints may increase the chance to 
identify promising treatments for MPM. 
• MPM is a heterogenous tumor, many molecular mechanisms including hypoxia, 
metabolism, microRNAs and gene-environment interaction should be the main 
areas for designing new promising therapeutic agents.    
• The lack of appropriate interest and funding for research into MPM has most 
certainly affected the opportunity to achieve dramatic progress in the treatment of 
this neoplasm. 
1. Introduction  
Malignant mesothelioma is a highly lethal and rare malignant neoplasm with poor prognosis 
[1]. Mesothelioma mainly arises from mesothelial cells lining the pleura (approximately 80% 
of cases; malignant pleural mesothelioma (MPM)) and peritoneum (approximately 20% of 
cases) whilst very rare mesothelioma cases have been reported to originate from the 
pericardium and tunica vaginalis [2]. Between the critical factors leading to mesothelioma, 
exposure to asbestos is considered the primary cause, as asbestos exposure results in of chronic 
inflammation in the mesothelium promoting the carcinogenic processes [3]. Radiation and 
simian virus 40 (SV40) are additional agents suspected to cause MPM [4]. Recently, it has been 
reported that individuals bearing BRCA1 associated protein-1 (BAP1) mutations could be 
genetically predisposed to MPM since families with germline BAP1 mutations develop MPM 
without any exposure to asbestos [5]. In addition, Nasu et al. reported that the high percentage 
of BAP1 mutations were found in sporadic MPM (>60%) suggesting that BAP1 is the most 
mutated gene in MPM and a potential “driver” in MPM pathogenesis [6]. Other relevant genes 
found highly altered in MPM patients are NF2 (75% of the cases) and CDKN2A (60% of the 
cases). MPM is characterized by three different histological subtypes: the most frequent is 
epithelioid, which has a better prognosis than the sarcomatoid and biphasic (mixed of 
epithelioid and sarcomatoid subtypes) histologies. MPM occurs most frequently in adult males, 
with a sex ratio of approximately 3.6:1. The disease is usually diagnosed 30 to 40 years after 
occupational asbestos exposure and the mean age at the diagnosis is usually at 70 years [7]. 
The lack of accurate and reliable biomarkers for detecting early stage of MPM makes this 
cancer very difficult to diagnose and treat leading to poor prognosis as the survival rate after 
diagnosis is around 9-14 months [8]. Recently, studies have shown that BAP1 
immunohistochemistry (IHC) and p16 fluorescence in situ hybridization (FISH) are reliable 
markers of malignancy in biopsies of mesothelioma [9]. Analysis based on 2008 data reported 
an average of 14 200 new cases registered each year worldwide [10]. The worldwide incidence 
of MPM has increased and it is estimated that a peak will be reached between 2015 to 2030. 
High incidence rates have been recorded in the USA, the UK, Australia and Italy [11] and it 
has been predicted to increase further in the future, in particular in developing countries where 
asbestos has not been banned yet [12]. 
 
Once MPM is diagnosed, clinical staging is used to assess a prognostic score and decide the 
best treatment option. The most used staging classification system is the American Joint 
Committee on Cancer (AJCC) staging system, that is based on TNM (tumour, node, metastasis) 
classification [13]. Treatment options vary according to the TNM stage of cancer. Surgery is 
recommended only for selected patients with early-stage disease and stable health conditions 
[12]. Other options are a multimodality regimen, which consists of a combination of 
chemotherapy, surgery, and radiotherapy. The current standard first-line systemic treatment is 
combination chemotherapy of cisplatin and antifolate [12]. Nevertheless, the clinical benefit of 
this combination treatment over other therapeutic approaches is not clear [7]. The reasons for 
the disappointing effects of current therapies are not clear, therefore there is an increased need 
to understand why some patients respond to immunotherapy and others do not. This review 
focusses on independent preclinical and clinical research related to mesothelioma selected by 
only the clinical trials funded by Universities, National Institutes of Health (NIH) and 
charitable organisations from https://clinicaltrials.gov/, closing with an expert opinion from a 
translational research team.  
 
 
1. Body 
1.1. The failure of the current treatments 
The current clinical trials for patients with MPM are mainly based on combination of standard 
chemotherapy plus one or more emerging agents (Table 1). In 2003, Vogelzang et al. published 
a clinical study which has been established as standard first line treatment using pemetrexed in 
combination with cisplatin for MPM patients in advanced stage disease but this combination 
confers a median progression-free survival (PFS) of 5.7 months [14]. Many other studies have 
been initiated to investigate the effect of combinatory treatments as first line treatment for 
MPM. For instance, Van Meerbeck et al. set a phase III trial which provided confirmatory 
evidence that a combination of cisplatin with an antifolate is superior to cisplatin alone [15]. 
Other phase II studies have employed cisplatin and gemcitabine [16,17], pemetrexed and 
carboplatin [18,19], bortezomib and cisplatin [20] but all have shown lack of improvement in 
overall survival (OS) and PFS. Most recently current standard chemotherapy is combined with 
additional drugs, for example, cisplatin and pemetrexed were combined with bevacizumab 
[21,22], or Imatinib Mesylate [23] with Amatuximab [24].  The most successful clinical trial 
is the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) where the OS is 
significantly improved by two months compared to chemotherapy only. 
Several biases are met in the clinical trials for MPM patients, which could be the cause of the 
ineffective current experimental therapies. The principal hallmarks for the design of high 
quality trials are randomisation, blinding, adequate power, and a clinically relevant patient 
population [25]. Mesothelioma clinical trials rarely met all these parameters mainly due to the 
size of the population investigated. MPM is an orphan disease because it is rare compared to 
other cancers and once it has been diagnosed the survival is very poor (less than one year), 
which poses difficulties in the investigation of the long-term effects of a studied drug. 
Moreover, this cancer has high genetic and phenotypic intra-tumoral heterogeneity with 
additional differences of the spatial and temporal evolution of MPM, during the treatment, 
which increases the complications on treatment decisions [26]. 
 
 
Table 1. Summary of complete clinical trials using chemotherapy with or without other treatments for 
MPM patients. The selected studies were funded by Universities, National Institutes of Health (NIH) and 
charitable organisations from https://clinicaltrials.gov/. 
 
Title # 
pts 
Phases Sponsor/Collaborators NCT Number 
Intrapleural Photodynamic Therapy in a 
Multimodal Treatment for Patients With 
Malignant Pleural Mesothelioma 
6 Phase II University Hospital, 
Lille|Institut National de 
la SantÃ© Et de la 
Recherche MÃ©dicale, 
France|University of 
Pennsylvania|RÃ©gion 
Nord-Pas de Calais, 
France 
NCT02662504 
Vascularity Impact on the Treatment 
Outcome in Malignant Pleural 
Mesothelioma(VITMPM) 
50   Ain Shams University NCT02603315 
Active Symptom Control With or Without 
Chemotherapy in Treating Patients With 
Malignant Pleural Mesothelioma 
840 Phase III Medical Research 
Council|National Cancer 
Institute (NCI) 
NCT00075699 
Isolated Thoracic Perfusion (ITP-F) for MPM 23   Medias Klinikum for 
Surgical Oncology 
NCT02467426 
Pemetrexed Disodium and Cisplatin Followed 
By Surgery and Radiation Therapy in 
Treating Patients With Malignant Pleural 
Mesothelioma 
59 Phase II European Organisation 
for Research and 
Treatment of Cancer – 
EORTC 
NCT00227630 
Pemetrexed Disodium and Cisplatin Followed 
by Surgery With or Without Radiation 
Therapy in Treating Patients With Malignant 
Pleural Mesothelioma 
153 Phase II Swiss Group for Clinical 
Cancer Research 
NCT00334594 
Mesothelioma Avastin Plus Pemetrexed-
cisplatin Study 
448 Phase 
II|Phase 
III 
Intergroupe Francophone 
de Cancerologie 
Thoracique|University 
Hospital, Caen|Groupe 
Francais De Pneumo-
Cancerologie 
NCT00651456 
Effect of FAS and FAS Ligand 
Polymorphisms on Patients With Platinum-
Based -Treated Malignant Pleural 
Mesothelioma 
68   Ain Shams University NCT02269878 
Study of Carboplatin and Vinorelbine in 
Malignant Pleural Mesothelioma 
40 Phase II Rigshospitalet, Denmark NCT00272558 
Gemcitabine in Long Infusion and Cisplatin 
for Malignant Pleural Mesothelioma 
Treatment 
78 Phase II Institute of Oncology 
Ljubljana|Ministry of 
Higher Education, 
Science and Technology, 
Solvenia 
NCT01243632 
Phase II Study of IMC-A12 in Patients With 
Mesothelioma Who Have Been Previously 
Treated With Chemotherapy 
20 Phase II National Cancer Institute 
(NCI)|National Institutes 
of Health Clinical Center 
(CC) 
NCT01160458 
Extrapleural Pneumonectomy /Pleurectomy 
Decortication, IHOC Cisplatin and 
Gemcitabine With Amifostine and Sodium 
Thiosulfate Cytoprotection for Resectable 
Malignant Pleural Mesothelioma 
141 Phase I Brigham and Women's 
Hospital|Dana-Farber 
Cancer Institute 
NCT00571298 
Pilot Study of Allogeneic Tumor Cell Vaccine 
With Metronomic Oral Cyclophosphamide 
and Celecoxib in Patients Undergoing 
Resection of Lung and Esophageal Cancers, 
Thymic Neoplasms, and Malignant Pleural 
Mesotheliomas 
10 Phase I National Cancer Institute 
(NCI)|National Institutes 
of Health Clinical Center 
(CC) 
NCT01143545 
A Phase II Study of PF-03446962 in Patients 
With Advanced Malignant Pleural 
Mesothelioma 
17 Phase II NCIC Clinical Trials 
Group|Canadian Cancer 
Trials Group 
NCT01486368 
Pleurectomy/Decortication Followed by 
Intrathoracic/Intraperitoneal Heated 
Cisplatin for Malignant Pleural Mesothelioma 
70 Phase I Dana-Farber Cancer 
Institute|Brigham and 
Women's Hospital 
NCT00165555 
Phase II Study of Bevacizumab, Pemetrexed 
and Carboplatin as First-Line Therapy in 
Malignant Pleural Mesothelioma 
77 Phase II Armando Santoro, 
MD|Istituto Clinico 
Humanitas 
NCT00407459 
Cisplatin With or Without Raltitrexed in 
Treating Patients With Malignant 
Mesothelioma of the Pleura 
256 Phase III European Organisation 
for Research and 
Treatment of Cancer – 
EORTC 
NCT00004920 
Cisplatin With or Without Pemetrexed 
Disodium in Treating Patients With 
Malignant Mesothelioma of the Pleura That 
Cannot be Removed by Surgery 
Null Phase III Memorial Sloan Kettering 
Cancer Center|National 
Cancer Institute (NCI) 
NCT00005636 
Cisplatin, Interferon Alfa, Surgery, and 
Radiation Therapy in Treating Patients With 
Malignant Pleural Mesothelioma 
6 Phase I Fox Chase Cancer 
Center|National Cancer 
Institute (NCI) 
NCT00003263 
Pemetrexed Plus Gemcitabine or Carboplatin 
for Patients With Advanced Malignant 
Pleural Mesothelioma 
32 Phase II Eastern Cooperative 
Oncology Group|National 
Cancer Institute 
(NCI)|North Central 
Cancer Treatment Group 
NCT00101283 
Pemetrexed, Cisplatin, and Vitamin B12 in 
Treating Patients With Mesothelioma of the 
Chest That Cannot Be Removed by Surgery 
60 Phase II Centre Oscar 
Lambret|National Cancer 
Institute (NCI) 
NCT00541073 
Decitabine in Treating Patients With 
Unresectable Lung or Esophageal Cancer or 
Malignant Mesothelioma of the Pleura 
Null Phase I National Cancer Institute 
(NCI) 
NCT00019825 
S9810: Gemcitabine Plus Cisplatin in 
Treating Patients With Malignant 
Mesothelioma of the Pleura That Cannot Be 
Removed by Surgery 
57 Phase II Southwest Oncology 
Group|National Cancer 
Institute (NCI) 
NCT00003723 
Combination Chemotherapy Before Surgery 
in Treating Patients With Mesothelioma of the 
Lung 
61 Phase II Swiss Group for Clinical 
Cancer Research 
NCT00030745 
Dendritic Cell-based Immunotherapy 
Combined With Low-dose Cyclophosphamide 
in Patients With Malignant Mesothelioma 
10 Phase I Erasmus Medical Center NCT01241682 
 
 
 
 
 
 
1.2. New potential targets in MPM  
2.2.1 Immunotherapy  
One of the “hot” topics regarding cancer treatment is immunotherapy which aims to educate 
immune system components to trigger an effective immune response to kill cancer cells. 
Several immunotherapeutic strategies have been developed and investigated [27]. 
Immunotherapy consists of multiple strategies including the engineering of antibodies or 
immune cells to enhance their anti-tumour effect or stimulating the immune system to induce 
an effective immune response [28]. This strategy has been investigated in several tumours and 
the FDA has approved immunotherapy for treating melanoma, lung cancer, kidney cancer, and 
other cancers [29-31]. Several clinical trials assessed the effect, safety and tolerance of 
immunotherapy in mesothelioma and here we reported only clinical trials that have been 
supported by NIH, Universities and no-profit organisations (Table 2) (Figure 1). 
An example of immunotherapy applied to mesothelioma is the use of immunotoxic antibodies 
against mesothelin. Mesothelin is a 40 kDa glycoprotein with low expression in normal human 
tissues and high expression in many cancers, therefore this protein is an attractive antigen for 
antibody‐based immunotherapy [32]. SS1(dsFv)PE38 (SS1P) is a recombinant immunotoxin 
against mesothelin that consists of a murine antimesothelin variable antibody fragment (Fv) 
bound to PE38, a truncated portion of Pseudomonas exotoxin A [32]. Two clinical trials have 
been assessed and supported by NIH, one (NCT01362790) investigated the effect of SS1P in 
combination with standard chemotherapy combination. The results showed that SS1P is well 
tolerated when given in combination with standard chemotherapy and 10 (77%) had a partial 
response, 1 had stable disease, and 2 had progressive disease [32]. The other study assessed 
how effective SS1P is when it is given with pentostatin and cyclophosphamide 
(NCT01445392). The results have not been published yet. 
Gene therapy in combination with immunotherapeutic option has been investigated in a phase 
I study using an adenoviral vector expressing interferon-β (Ad.IFN-β) in 17 patients with 
malignant pleural mesothelioma or malignant pleural effusions (NCT00066404)[33]. After 2 
months, modified (Response Evaluation Criteria in Solid Tumors) RECIST responses were as 
follows: one partial response, two stable diseases, nine progressive diseases, and two non-
measurable diseases. One patient died after 1 month. 
One of the most adopted immunotherapy strategies for cancer treatment is use of antibodies 
that block immune checkpoints. These monoclonal antibodies inhibit the immune checkpoints 
by preventing the receptors and ligands from binding to each other, thereby blocking the 
signalling that promotes cancer survival by evading T-cell-mediated death [34]. The immune 
checkpoint receptors cytotoxic T lymphocyte-associated 4 (CTLA-4) and programmed cell 
death protein 1 (PD-1) are expressed on the surface of cytotoxic T-cells and interact with their 
ligands binding of B7-1 (cluster CD80) and programmed death ligand-1 (PDL-1) on antigen 
presenting cells to promote cancer survival [35]. Several immune checkpoint inhibitors have 
been approved including ipilimumab (an anti-CTLA-4 agent), nivolumab and pembrolizumab 
against anti-PD-1, nivolumab, and pembrolizumab as PDL-1 inhibitor, atezolizumab against 
PDL-1 for treating cancers such multiple melanomas, lung and ovarian cancer [36]. 
Pembrolizumab has been investigated alone (NCT02399371) in MPM patients previously 
treated in a phase II study. 35 patients were enrolled and the median PFS was 6.2 months and 
median OS has not been reached with a high level of toxicity (grade 3/4 and 1/2). Nivolumab 
(Nivo) and ipilimumab (Ipi) have been assessed as 2nd/3rd line treatment in 125 patients. 
Generally, disease control rate (DCR) is <30% with the current drugs tested in 2nd-line but the 
results from the phase II clinical trials reported that twelve weeks-DCR was 42.6% with Nivo, 
and 51.9% with Nivo+Ipi. In the combo arm, grade/G3-4 toxicities were slightly increased 
compared to Nivo alone (86.9%/16.4%) vs (77.8%/9.5%) and 3 treatment-related deaths were 
observed [37]. 
Dendritic cell-based immunotherapy includes vaccinations based on the use of dendritic cells 
(DCs). DCs are the most potent APCs and induce the activation and proliferation of cytotoxic 
CD8+ and helper CD4+ T lymphocytes to eliminate cancer cells [38]. DCs vaccines are 
developed ex vivo and injected as tumour antigen pulsed dendritic cells [39]. This therapeutic 
approach has been investigated in mesothelioma. The administration of tumour lysate-pulsed 
dendritic cells was assessed in a clinical trial with 9 patients with mesothelioma. The aim of 
the study was to evaluate the safety and immunological response induced by the treatment. The 
results showed that the vaccination was safe with no grade 3 or 4 toxic effects, only moderate 
fever and after three vaccinations, cytotoxic activity against autologous tumour cells were 
detected in a subgroup of patients. Median survival was 19 months but nine patients died of 
disease; one patient is alive with disease (NCT02395679)[40]. Although immunotherapy has 
some beneficial effects on some solid tumours, in MPM the response has been disappointing so far and 
there are many concerns with regard to its true impact [8]. Since the role of the immune system in MPM 
is multifaceted, research should focus on the tumour microenvironment characteristics such hypoxia 
and the chronic inflammatory state, tumour-associated macrophages (TAMs), T regulatory cells and 
cancer-associated fibroblasts. In addition, the interaction of genetic instability and the environment 
promote even further the development and progression of this cancer. Therefore, targeting one of these 
pathways or a combination could provide promising outcomes when combined to immunotherapy and 
the only way to achieve these results is funding basic research not directly aimed at the translation of 
what already known for other tumours but paving new MPM-tailored immunotherapies[41-43].        
 
2.2.2 Multi-targeted therapy 
2.2.2.1 Tyrosine-kinase inhibitors (TKI) 
For the past decades, the knowledge about cancer biology has increased exponentially, 
therefore to overcome the low clinical benefit of chemotherapeutic approaches, clinical and 
experimental research was focussed on developing and investigating the role of small molecule 
inhibitors to target several molecular pathways involved in carcinogenesis. The first molecules 
that were targeted are growth factors, which promote uncontrolled tumour growth and tumour 
angiogenesis. These molecules are part of a big family of transmembrane tyrosine kinase 
receptors (TKRs), including epidermal growth factor receptor (EGFR), insulin-like growth 
factor (IGF) and vascular endothelial growth factor receptors (VEGFRs) [2]. Several studies 
showed that EGFR protein is overexpressed in more than 50% of MPM cases. From five 
clinical trials enrolling mesothelioma patients treated with erlotinib, four were sponsored by 
NIH or other sponsors (Table 2). A phase II study enrolled 63 previously untreated MPM 
patients to investigate the effect of erlotinib. Immunohistochemical analysis of EGFR has 
shown that 75 % of patients tumours highly expressed EGFR, but nonetheless, there was no 
response for 33 patients with measurable disease, median OS was 10 months and PFS was only 
2 months. Therefore, single-agent erlotinib was not effective in MPM (NCT00039182) [44]. 
Another phase II study investigated the response rate, progression, survival, and toxicity of 
erlotinib with bevacizumab in 24 patients previously treated with one chemotherapy regimen. 
Complete or partial response was not achieved and OS was 5.8 months and PSF 2.2 months 
(NCT00137826)[45]. Another drug inhibiting EGFR is gefitinib that has been assessed in a 
phase II study in previously untreated malignant mesothelioma patients. 43 patients were 
enrolled and one1 (2%) had a complete response, one (2%) had a partial response and 5 (12%) 
had an early death. Although the majority of mesothelioma patients had EGFR overexpression, 
gefitinib was not effective in malignant mesothelioma. Another class of small inhibitors has 
been studied in mesothelioma patients that target vascular endothelial growth factor (VEGF) 
and its receptor VEGFR. Studies have shown high levels of both molecules in MPM tissue 
specimens (NCT00025207)[46]. Numerous anti-VEGF/VEFGR inhibitors have been 
independently assessed in malignant mesothelioma including cediranib[47], sunitinib[48], and 
vatalanib[49] demonstrating no effect or poor activity, with no clinical benefits. SV40-
dependent Akt pathway has been found upregulated in malignant mesothelioma, which protects 
against cell death in HMC and malignant mesothelioma cells after amosite (a particular kind 
of asbestos) exposure, therefore targeting this pathway may make MPM patients sensitive to 
chemotherapy. Therefore, TKR activating mutations are not the main responsible for MPM 
resistance rather SV40-positive human mesothelial cell and exposure to amosite fibers for long term 
promotes cell survival via Akt Activation[50].  
 
2.2.2.2 Antibodies based therapy  
Antibodies have been developed against growth factors such as IFG-1 and VEGF. 
Cixutumumab, a monoclonal antibody that selectively inhibits ligand binding to IGF-1R, was 
tested in mesothelioma patients since in vitro and preclinical studies demonstrated tumour 
reduction after cixutumumab treatment. A phase II study has been conducted for previously 
treated MPM patients but the results are not available. Bevacizumab (Avastin) is the most 
encouraging drug that targets VEGF signalling which is a humanized monoclonal antibody 
against VEGFA. Bevacizumab was approved in the EU in 2005 for the treatment of many solid 
cancers such as non-small cell lung cancer (NSCLC), colorectal carcinoma and renal cell 
cancer [51-53] (Figure 1). From seven clinical trials for bevacizumab, five have been 
accomplished and sponsored by NIH or other sponsors. Bevacizumab has been investigated in 
combination with standard chemotherapy. Bevacizumab was evaluated in combination with 
gemcitabine and cisplatin in a randomized, double-blind, placebo controlled study in 115 MPM 
patients (NCT00027703). There were differences in response between bevacizumab and 
placebo arms (PFS; 6.9 vs 6.0 months) and OS (15.6 vs 14.7 months) [54]. Bevacizumab was 
also tested in combination with carboplatin and pemetrexed in a Phase II study in patients with 
unresectable MPM. The median PFS was 6.9 months and the median OS was 15.3 months and 
the study failed to achieve the primary endpoint of 50 % improvement in PFS compared to 
standard chemotherapy [54]. Another phase II study investigated the combination of 
bevacizumab with pemetrexed and cisplatin in 53 patients with previously untreated and 
unresectable mesothelioma (NCT00295503). Although the treatment was well tolerated, it 
failed to achieve its primary endpoint of 33% improvement in PFS at 6 months [21]. 
 
Novel anticancer agents including histone deacetylase (HDAC) inhibitors, nuclear factor-κB 
(NF-κB) pathway inhibitor, anti-TGFβ monoclonal antibody, and anti-Met small inhibitors are 
all currently under investigation. Belinostat targets HDAC which regulates epigenetic 
mechanisms of tumour suppressor genes through chromatin remodelling with tumourigenic 
effects [55]. A phase II trial was designed to analyse the effect of belinostat as second-line 
treatment in patients with MPM (NCT00365053). 13 patients were enrolled but belinostat was 
not effective as a single second-line therapy in MPM patients [56]. Bortezomib is a specific 
proteasome inhibitor that promotes downregulation of NF-κB and stimulates apoptosis. 
Although preclinical results were encouraging, the results showed low clinical activity and high 
toxicity in a Phase II study in pre-treated patients with MPM [57]. GC1008 is a neutralizing 
anti-TGFβ antibody and its clinical safety and median survival were the main aims of this Phase 
2 study [58] (Figure 1). 13 pre-treated MPM patients participated to the study and the results 
reported that GC1008 is well tolerated; however, there was an indication that the treatment 
might promote the malignant cell growth in a few patients. 
Ultimately in hindsight, the front-line treatment for MPM is based on pemetrexed, cisplatin, 
and bevacizumab, as these are the treatments shown to significantly improve patient survival. 
Notably, for bevacizumab, this treatment was based on solid preclinical experiments that 
proved VEGF to be an autocrine growth factor for mesothelioma [59]. Furthermore, it was also 
shown that high serum VEGF levels are linked with poorer patient prognosis and therefore 
represents a clear example of the kind of independent research that promoted pharmaceutical 
organisations to invest.  
 
 
Figure 1 Summary of recent therapeutic agents tested in mesothelioma and potential targets.  
Immunotherapy includes; antibody (Ab) targeting immune checkpoints (programmed cell death-1 and 
programmed cell death ligand 1; PD-1/PDL-1, cytotoxic T-lymphocyte–associated antigen 4; CTLA4) and 
immunotoxin Ab targeting mesothelin (SS1P). An example of gene therapy is an adenoviral vector expressing 
interferon-β (Ad.IFN-β) and vaccines have been tested with mature dendritic cells (DCs) engineered to express a 
tumour antigen. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGFA). 
GC1008 is a neutralizing anti-TGFβ (Transforming growth factor β) antibody. Small inhibitors include anti-EGFR 
(epidermal growth factor receptor) and anti-VEGFR (vascular endothelial growth factor receptor). HIF-α, 
Hypoxia-inducible factor 1-α, miR (microRNA) TargomiR is a strategy that uses minicells carrying mimic miR-
16 function. 
 
2.3 How repositioning drugs can help mesothelioma therapy 
Drug repositioning is a potential approach for the identification of new therapeutic use for 
already approved drugs. The majority of biochemistry and clinical proprieties such as 
bioavailability and safety profiles, proven formulation and manufacturing routes, and 
reasonably characterized pharmacology, are known for most approved molecules which favour 
the inclusion of these repositioned drugs in clinical phases more rapidly and at a lower cost 
than novel therapeutic agents [60]. For rare diseases such as mesothelioma that are 
understudied at the preclinical and clinical levels, the development of new compounds is 
problematic and needs worldwide collaboration from numerous clinical trial centres in order 
to achieve successful outcome from innovative drugs. Drug repositioning may be an attractive 
strategy for diseases such as mesothelioma, by offering a reduced timeframe from preclinical 
research to the bedside [61]. Furthermore, with the expected increase of incidence of MPM in 
developing countries, drug repositioning could offer solutions for patients living in these 
countries. Repositioning may apply to a wide variety of drugs (see subsequent sections) and be 
performed in a variety of ways. Recent research used the DRUGSURV database [62] to target 
individual genes/proteins that were identified as important for mesothelioma based on 
computational modelling of TP53 and stratified patient data [63](Figure 2). 
 
Other approaches include drug/molecular docking; this is one of the most powerful approaches 
for structure-based discovery [64], as it predicts the interaction between small molecule ligands 
and targets (such as proteins that are targeted for inhibition or modulation). There are numerous 
softwares available to conduct this, including PyRx which, in conjunction with other software 
and resources, has been applied in the past to identify small molecule inhibitors that break the 
interaction between TP53 (obviously highly important for cancer) and its inhibitors [65]. 
Applied to mesothelioma, drug docking could utilise databases such as the ZINC database 
(which offers structures for approved drugs as well as experimental drugs [66]) to obtain drug 
structures and perform an in silico screen of these drugs against proteins that are believed to be 
important for mesothelioma development. This approach could, therefore, identify repositioned 
drugs in a molecular structure-based approach. The below sections will cover a variety of 
repositioned drugs and how they may apply to mesothelioma. 
  
2.3.1 Antiemetic drugs 
One of the first repositioned drugs is thalidomide, an antiemetic drug, used in the past for 
morning sickness in pregnant women with detrimental consequences because of its teratogenic 
effects [67]. Later, it has been demonstrated that thalidomide has anticancer proprieties and 
therefore it has been assessed in several human cancers in clinical trials, which led to its 
approval for the treatment of multiple myeloma [68]. In MPM, thalidomide has been evaluated 
in clinical trials without prior investigations in preclinical models. A phase II clinical study 
investigated the efficacy and toxicity of thalidomide in patients with MPM. The promising 
results showed that 27.5% of previously treated patients and treated with thalidomide as a 
single agent had disease stabilization for >6 months and the median survival was 230 days. 
These results warrant phase III studies in MPM [69]. Unfortunately, in a randomised phase III 
study thalidomide failed to improve OS, 10.6 months in the thalidomide group versus 12.9 
months in the active supportive care group in patients with MPM after first-line therapy in 
chemotherapy [70].  
 
2.3.2 Histone deacetylase inhibitors  
Valproate is another drug widely used as an antiepileptic drug and found to have several 
anticancer effects through its HDAC inhibiting activity [71]. In addition, it has been shown that 
valproate induced tumour differentiation, reduced tumour growth and metastasis formation and 
promoted apoptotic cell death [72]. Therefore, valproate has been assessed in clinical trials for 
treating several cancers including glioblastoma and cervical cancer [73,74]. Valproate has also 
been evaluated in preclinical and clinical research in patients with MPM. The synergistic 
activity of valproate in combination with chemotherapy contributed to the design of a phase II 
trial to investigate valproate in combination with doxorubicin in patients with refractory or 
recurrent MPM after standard first-line chemotherapy [75,76]. Among 45 patients, seven 
(16%) obtained a partial response. The median PFS was 2.5 months and the median OS was 
6.7 months [76]. 
 
2.3.3 Statins 
Another class of compounds frequently used for drug repositioning is statins. Generally, statins 
are used for the treatment of hypercholesterolemia and related atherosclerotic diseases, such as 
coronary artery disease. Statins also have anticancer proprieties [77] and have been intensely 
examined in vitro in human MPM cells. Rubins et al. demonstrated that Lovastatin decreased 
cell viability in a dose-dependent manner in human MPM cell lines, through apoptosis 
induction [78]. Another study showed that the combination of lovastatin and valproate reduced 
cell invasion of Acc-Meso-1 cells [79]. A synergistic effect of pemetrexed in combination with 
simvastatin induced apoptosis in MSTO-211 MPM cells by reactive oxygen species-dependent 
mitochondrial dysfunction and Bim induction as reported by Hwang et al. [80]. It has also been 
shown that statins have a role in the reversal of doxorubicin resistance by accumulating nitric 
oxide species in human MPM cells. Furthermore, statins have been shown synergistic 
antiproliferative effects with γ-tocotrienol (an isoform of vitamin E) on human MPM cells, via 
inhibition of the mevalonate pathway, induction of endoplasmic reticulum stress and caspase 
3 activations [81]. The potential to reposition lovastatin has also been demonstrated in vivo. 
The drug reduced primary tumour and metastasis in a NOD/SCID/ γ-null (NOG) mouse model 
of human MPM [82]. However, the role of statins in MPM has not yet been investigated in 
clinical trials. 
 
2.3.4 Antifungal drugs 
Itraconazole is generally administrated as broad-spectrum anti-fungal agent but it has been 
demonstrated in vivo, in vitro, and through clinical research that it has several antineoplastic 
properties [83]. Itraconazole decreased the viability in a dose-dependent manner by decreasing 
Gli1 expression, which is a key factor of the hedgehog pathway in various human MPM cell 
lines of epithelioid, sarcomatoid and biphasic subtypes [84]. However, itraconazole is yet to be 
assessed in vivo or in a clinical trial in MPM. 
Arsenic trioxide (ATO), a traditional Chinese medicine, has also been used for cancer 
treatment. Nonetheless, it has a high grade of toxicity, it was repositioned in western medicine 
and ATO was approved for the treatment of relapsed or refractory acute promyelocytic 
leukemia by the U.S. Food and Drug Administration in September 2000 [85]. ATO treatment 
has been also evaluated on human MPM cells, in the NCI-H2052 MPM cell line ATO cause 
apoptosis by activating c-JunNH2-terminal kinase (JNK)1/2, and the extracellular signal-
regulated kinase (ERK) pathway [86]. An antiproliferative effect and cytotoxic effect of ATO 
[62] was also reported in vitro and in vivo in MPM by apoptosis induction mediated through 
downregulation of E2F1 and downregulation of thymidylate synthase, which is involved in 
pemetrexed resistance when overexpressed [87]. 
 
2.3.5 DNA methyltransferase inhibitors 
Disulfiram (DSF) is a drug of the dithiocarbamate family and is an irreversible inhibitor of 
aldehyde dehydrogenase approved by the FDA to treat alcoholism [88]. It has also 
demonstrated to inhibit tumour growth since DSF has epigenetic properties as a DNA 
methyltransferase inhibitor [89].  
In human MPM DSF has been studied in vitro together with copper to induce cytotoxicity, 
demonstrating that DSF–copper (DSF-Cu) complex inhibited proliferation of MPM cell lines 
and induced apoptosis [90]. Moreover, the inhibition of tumour growth was confirmed in vivo 
model, showing a 71% decrease of tumour growth when compared to control tumours [90]. 
 
2.3.6 Nonsteroidal anti-inflammatory drugs 
Acetylsalicylic acid or aspirin prevents the function of cyclooxygenase (COX)-1 and COX-2 
and is mainly used as a nonsteroidal anti-inflammatory drug but has been shown to promote 
apoptosis and suppresses the acquisition of chemoresistance [91]. Aspirin has been investigated 
in human MPM cell lines showing the inhibitory effect on colony formation by secreting high 
amounts of high-mobility group box (HMGB)1, a protein that regulates nucleosome assembly 
and chromatin structure [92]. The antiproliferative effect of aspirin on MPM cells was 
confirmed in vivo [92]. However, Aspirin has not yet been tested in clinical trials in MPM 
patients. 
Celecoxib is a selective COX-2 inhibitor [66] approved by the FDA since December 1999 in 
familial adenomatous polyposis [93]. In MPM, celecoxib decreased prostaglandin E2 levels in 
AB1, a murine MPM cell line [94]. The effect of celecoxib has also been evaluated in vivo in 
BALB/c mice xenografted using AB1 cells, however clinical assessment of the role of COX-2 
in MPM is still missing. 
 
2.3.7 Oral antidiabetics 
Metformin is a biguanide derivative, which is prescribed for type 2 diabetes. Metformin may 
act as an anticancer drug that promotes apoptosis, cell cycle arrest and invasion [95]. In MPM, 
the influence of metformin on the intercellular transfer of cellular contents has been assessed 
in cell lines of the biphasic, sarcomatoid and epithelioid types. Metformin suppressed 
tunnelling nanotube formation in vitro [96]. Regardless of this effect, metformin did not 
significantly reduce cell proliferation. So far, metformin has not been investigated in vivo or in 
clinical trials in MPM. 
 
2.3.8 Vitamin E isoform  
It is known that vitamin E has a role in cancer acting as an antioxidant adjuvant. Tocotrienol 
(T3) is an isoform of vitamin E which has an effect on NF-κB, signal transducer and activator 
of transcription (STAT) 3, apoptosis, nuclear factor (erythroid-derived 2)-like 2, hypoxia-
inducible factor 1 (HIF-1), growth factor receptor kinases, and angiogenic pathways [97]. 
Tocotrienol-rich fraction extracted from rice and source of γ-T3 synergizes with cisplatin 
reducing the chemoresistance in H28, a human cisplatin-resistant MPM cell line [98]. In 
addition, the combination of γ-T3 with statins promoted an antigrowth effect on human MPM 
cells through reduction of the mevalonate pathway, induction of endoplasmic reticulum stress 
and caspase 3 activations [81]. γ-T3 has not been investigated in vivo or in clinical trials in 
MPM. 
α-tocotrienol is another isoform of tocotrienol with pro-apoptotic anticancer properties, its 
redox-silent analogue, 6-O-carboxypropyl-α-tocotrienol (T3E), has been tested in vitro in 
human MPM cells which inhibited the cell proliferation of human MPM H28 cells [99]. α-T3 
has not been investigated in vivo or in clinical trials in MPM. 
 
2.3.9 Antibiotics 
Anisomycin is an antibiotic produced by Streptomyces griseolus and acts as a protein synthesis 
inhibitor, low dose of anisomycin enhanced the sensitivity to TNF-related apoptosis-inducing 
ligand (TRAIL) in mesothelioma cells [100]. This sensitisation enhanced the activity of Bim 
by post-translational modifications which primes the cells for apoptosis via the death receptor 
pathway. These data have not been confirmed in vivo or in clinical trials. 
 
2.3.10 Bisphosphonates 
Bisphosphonates are approved for treatment of bone lesions such as osteoporosis, cancer-
induced osteolytic bone disease and hypercalcaemia [101]. Moreover, nitrogen-containing 
bisphosphonates such as zoledronic acid (Zol) have anticancer effects [102]. In vivo and in 
vitro experiments in mesothelioma showed that Zol induced apoptosis and S-phase arrest in a 
p53-independent manner[103]. Several clinical trials have been assessed the effect of Zol in 
mesothelioma patients. A study by Jamil et al. [104] examined the effect of single agent Zol in 
a small group of patients with MPM who had progressed after one or more prior systemic 
therapies. Among eight pretreated patients, the median PFS was 2 months and the median OS 
was 7 months without significant toxicity. Another study by Clive et al. [105], looking at the 
role of Zol in malignant pleural effusions, showing that two patients with MPM had a reduction 
in tumour bulk on radiology after receiving two doses of ZA intravenously. A recent 
multicentre double-blind randomised controlled feasibility study aims to assess the recruitment 
and acceptability of Zol/placebo alongside chemotherapy in MPM[106]. 
 
 
Figure 2 Examples of drugs repositioning in mesothelioma.  
Abbreviations: NADH; nicotinamide adenine dinucleotide, ATP; Adenosine triphosphate, COX-2; 
Cyclooxygenase-2, VDAC; Voltage-dependent anion channel, CoA; coenzyme A reductase, HMG; 3-hydroxy-3-
methylglutaryl, FPP; farnesyl pyrophosphate, GPP; geranyl pyrophosphate, ER; endoplasmic reticulum, HDAC; 
histone deacetylases, NF-κB; nuclear factor kappa-light-chain-enhancer of activated B cells, VEGFR; vascular 
endothelial growth factor receptors, VEGF; vascular endothelial growth factor. 
 
 
 
2.4 Discovery of new small molecules 
Basic research has led to the discovery of new pathways relevant to the development of MPM, 
and the latest studies focussed on mechanisms involved mainly in tumour microenvironment 
such as hypoxia, caused by the lack of oxygen and formation of the abnormal tumour blood 
vessels. In 2006, Klabatsa et al described that mesothelioma and not mesothelial cells 
overexpressed HIF-1α corresponding with the presence of hypoxia [107]. Later, it has been 
demonstrated with [F-18] fluoromisonidazole (FMISO) PET-CT that there are significant areas 
of hypoxia, particularly in dominant tumour masses, in mesothelioma patients, therefore 
mesothelioma may be considered a hypoxic tumour [108]. One study investigated which 
pathways are induced by hypoxia to promote aggressive phenotypic changes in human 
mesothelioma cell lines. The high CD44 cell population of mesothelioma cells was 
significantly increased in hypoxia when compared with normoxia. In addition, hypoxia 
significantly increased the resistance of mesothelioma cells to cisplatin. While cisplatin 
treatment decreased in normoxic condition and hypoxia also increased the ratio of Bcl-2 to Bax 
in mesothelioma cells treated with cisplatin. Hypoxia promoted the mobility, invasiveness and 
epithelial to mesenchymal transition of HMM cells [109]. Although targeting hypoxia seems 
promising and topotecan, YC-1, PX-478 are compounds targeting directly hypoxia through the 
inhibition of HIF-1, they have not been tested in clinical trials in mesothelioma [110]. 
MicroRNAs (miRNAs or miRs) are other small regulatory molecules widely investigated in 
cancer since their deregulation influences tumorigenesis. Since they are small circulating 
molecules, they are mainly studied as biomarkers for diagnostic and prognostic aims. A study 
reported that MiR-185, miR-197, and miR-299 were differentially expressed in MPM samples 
compared to healthy pleura. Two-miRNA prognostic signatures were identified Let-7c-5p and 
miR-151a-5p which are linked to hypoxia and energy metabolism respectively [111]. It has 
been found that miRNA-31 induced chemoresistance though an ABCB9-independent 
mechanism in MPM[112]. The only current clinical trial that assesses the role of miRNAs as a 
therapeutic tool in mesothelioma is based on testing a miR-16 mimic (Table 2). In an in vivo 
study, miR-16-loaded minicells called  EDVTMnanocells (EDVs) were able to control tumour 
growth in a dose- and frequency-dependent manner, with the highest dose (administered four 
times per week), completely inhibiting tumours [113]. Following these data, a phase I study in 
MPM and NSCLC patients (‘MesomiR 1’) is currently assessing the safety and dose-escalation 
of TargomiRs (NCT03531840). Authors found that the maximum tolerated dose was 5 × 109 
TargomiRs once weekly. One (5%) had a partial response, 15 (68%) had stable disease, and 
six (27%) had progressive disease and 21 (78%) deaths occurred, of which 20 were related to 
tumour progression and one was due to bowel perforation [114](Figure 1). Another innovative 
field is tumour metabolism that is acquiring more importance in mesothelioma. Mesothelioma 
cells are mainly glycolytic dependent even in the presence of oxygen (Warburg effect), 
therefore targeting glycolytic pathway may be a successful strategy to target cancer cells. 
Citrate, an inhibitor of phosphofructokinase (PFK) has been tested in chemoresistant 
mesothelioma cell line and the results showed that the inhibition of PFK by citrate in addition 
to depletion of ATP, diminution of the expression of the anti-apoptotic proteins and inhibition 
of hexokinase may promote the cytotoxic and synergistic effect with cisplatin [115]. Another 
study found that the secreted frizzled-related protein 4 (sFRP4), a Wnt inhibitor may reduce 
and alter cancer cell metabolism, leading to sensitisation of cancer cells to chemotherapeutics 
and cell death [116]. Other potential therapeutic targets are excitatory amino acid transporters, 
a glutamate carrier, Dishevelled3, an activator of the Wnt pathway and glutamine synthetase 
[117]. Recent findings indicate that the BAP1 gene has a crucial function in mesothelioma. In 
vitro studies demonstrated that BAP1 regulates Ca2+ flux by stabilization of inositol-1,4,5-
trisphosphate receptor expression promoting apoptosis [118]. In addition, it has been 
demonstrated that BAP1+/− fibroblasts enhanced aerobic glycolysis and lactate secretion, in 
contrast, they decreased mitochondrial respiration and ATP production in comparison with 
BAP1 wild type (WT) [118]. However, a phase II clinical trial is recruiting patients with WT 
and mutant BAP1 to investigate whether patients with BAP1 mutations are more responsive to 
olaparib, a Poly (ADP-ribose) polymerases inhibitor that has been approved for treating 
germline and somatic BRCA1-mutant ovarian cancer. Since BAP1 is associated with BRCA1 
activity, this trial may provide promising results (NCT03531840) (Table 2). 
 
Table 2. Summary of clinical trials of new potential drugs in MPM 
 Target  Drugs  Combinations  Phase
s  
Sponsor/ 
Collaborators 
NCT Number 
Immunotherapy Mesothelin  
 SS1P  CDDP-PEM Phase 
I 
National Cancer 
Institute (NCI) NCT01445392 
  
SS1P  Pentostatin/Cycl
op 
Phase 
I/II 
National Cancer 
Institute (NCI) 
NCT01362790 
 PD-1 Pembrolizumab Alone Phase 
II 
University of 
Chicago 
Collaborator: 
National Cancer 
Institute (NCI) 
NCT02399371 
 Gene 
therapy 
 
 
Adenoviral-
mediated IFN-β 
BG00001 
 
 
 Phase 
I 
Abramson Cancer 
Centre of the 
University of 
Pennsylvania 
Collaborator: 
National Cancer 
Institute (NCI) 
 
NCT00066404 
 
Tyrosine-kinase 
inhibitors (TKI) 
Dendritic 
Cell-based 
vaccine 
 
Tumour lysate-
loaded 
autologous 
dendritic cells 
  
Phase 
I 
Erasmus Medical 
Centre 
 
NCT02395679 
 
 EGFR 
Erlotinib  Alone Phase 
II 
National Cancer 
Institute (NCI) 
NCT00039182 
  
Erlotinib Bevacizumab Phase 
II 
National Cancer 
Institute (NCI) 
NCT00137826 
  
Gefinitib 
(ZD1839, 
Iressa) 
 Phase 
II 
National Cancer 
Institute (NCI) 
NCT00025207 
 
 
Antibodies based 
therapy 
Anti-
angiogenesis 
inhbitors  
 
 
Bevacizumab 
 
 
 
 
Phase 
II 
 
University of 
Texas 
Southwestern 
Medical Centre 
Collaborators: 
University of 
Chicago 
Columbia 
University 
Duke University 
Information 
provided by 
(Responsible 
Party): 
Jonathan E. 
Dowell, University 
of Texas 
Southwestern 
Medical Centre 
NCT00295503 
 
 
 
 
 
 
 
 
NCT00027703 
 
National Cancer 
Institute (NCI) 
 Histone 
deacetylase 
inhibitors 
Belinostat 
  
Phase 
II 
 
National Cancer 
Institute (NCI) 
NCT00365053 
Discovery of new 
small molecules 
A miR-16-
based 
microRNA 
mimic 
TargomiRs  Phase 
I 
Asbestos Disease 
Research 
Foundation 
NCT02369198 
 PARP 
inhibitor 
Olaparib  Phase 
II 
National Cancer 
Institute (NCI) 
NCT03531840 
 
 
Add conclusions  
 
2. Expert Opinion 
The lack of appropriate interest and funding for research into MPM has most certainly affected 
the opportunity to achieve dramatic progress in the treatment of this neoplasm. As has become 
clear throughout this manuscript, a recurring issue that has been seen is that there is an 
insufficient bedrock of preclinical research to support translation to the clinic. Unfortunately, 
what has often been done is to attempt to reapply existing drugs that have shown success in 
other cancer types to treat mesothelioma. Whilst faster, this approach demonstrates its frailty 
through for example the use of tyrosine kinase inhibitors and, despite high hopes, 
immunotherapy, both of which have shown limited benefit for MPM. Should we desire to 
significantly improve MPM patient survival, it must first be acknowledged that there is still a 
long way to go. 
Recent findings regarding MPM gene-driven metabolism provide new opportunities to stratify 
patients on the specific biological characteristics of this tumour. These studies also allow 
identification of a broad range of newly identified specific targets for MPM that may represent 
a significant improvement for patients in the near future. To achieve these results, specific 
independent investments are necessary. As stated, the approach of adopting drugs that have 
shown benefit in other tumours is of low clinical benefit, and therefore investment into new 
ideas leading to new therapies for this “niche” tumour would be beneficial, particularly with 
targeted drug repositioning that is based on a solid scientific rationale, complemented by good 
clinical trial design and effective endpoints such as overall survival. 
Our hope is that over the next few years the research groups currently investigating MPM will 
find a way to integrate their knowledge and that grant submission systems will allow for the 
submission of team-oriented multidisciplinary project/programmes to cope with this upcoming 
demand of solid translational research for MPM. MPM is characterised by a low mutational 
load which complicates finding tailored therapy for this illness. However, as quoted above,  
there has been a recent surging flow of data to unravel how gene-driven metabolism[118] 
affects MPM cell growth and hinders response to standard treatments. These achievements, 
together with the pathway through which these effects are exerted, are of potential huge interest 
and many efforts being aimed at their validation is currently underway. Such validated results 
will provide solid data for patients to reasonably rely on to continue to hope. Therefore, we 
also believe that independent research should be imbued by pure passion and dedication, which 
will help in coping with patient demands. 
It has recently been shown via a retrospective study of precision medicine from 2006 to 2018 
that the portion of patients who can benefit of precision treatments increased very little when 
compared with all the resources deployed in this direction:  from 0.70 % in 2006 to 4.90 % in 
2018 [119]. It seems reasonable to figure out that we need better multi-disciplinary integration 
to accelerate our achievements in this field.    
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